<DOC>
	<DOCNO>NCT00905307</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study design assess tolerability , safety , efficacy OPC-34712 ( 0.25 6.0 mg ) treatment adult subject hospitalize acute relapse schizophrenia . Aripiprazole ( 10 20 mg ) include positive control confirm assay sensitivity study . A total approximately 563 subject screen estimate 75 site worldwide order obtain approximately 450 randomized subject .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability Oral OPC-34712 Aripiprazole Treatment Acute Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Male female subject 18 65 year age , diagnosis schizophrenia , define DSMIVTR criterion 2 . Subjects recently hospitalize would benefit hospitalization acute relapse schizophrenia 3 . Subjects experience acute exacerbation psychotic symptom 1 . Females breastfeed and/or positive pregnancy test result prior receive study drug 2 . Subjects current DSMIVTR Axis I diagnosis : Schizoaffective disorder MDD Bipolar disorder Delirium , dementia , amnestic cognitive disorder Borderline , paranoid , histrionic , schizotypal , schizoid antisocial personality disorder 3 . Subjects present first episode schizophrenia 4 . Other protocol specific inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Relapsed</keyword>
</DOC>